Literature DB >> 21421261

MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.

Catherine Thériault1, Maxime Pinard, Marina Comamala, Martine Migneault, Julie Beaudin, Isabelle Matte, Marianne Boivin, Alain Piché, Claudine Rancourt.   

Abstract

OBJECTIVES: MUC16 (CA125) protein is a high molecular weight mucin overexpressed in the majority of epithelial ovarian cancers (EOC) but not in the epithelium of normal ovaries suggesting that it might play a role in EOC pathogenesis. Here, we explored the phenotypic consequences of MUC16 knockdown and expression of its C-terminal domain with the aim of establishing a role for MUC16 in tumorigenesis.
METHODS: MUC16 was down-regulated by stably expressing an anti-MUC16 endoplasmic reticulum-targeted single-chain antibody which prevented MUC16 cell surface localization in NIH:OVCAR3 cells. In addition, we generated epitope tagged, N-terminal region-deleted MUC16 constructs with (MUC16TMU) and without (MUC16CTD) cytoplasmic tail deletions and stably expressed them in SKOV3 cells.
RESULTS: Although MUC16 knockdown did not affect the cell growth rate, knockdown cells reached a stationary growth phase after 4 days whereas control cells continued to grow for up to 7 days. Colony formation assays in soft agar demonstrated that MUC16 knockdown cells had >8-fold reduction in their ability to form colonies. Importantly, MUC16 knockdown completely prevents the formation of subcutaneous tumors in nude mice. Conversely, we show that ectopic expression of the MUC16CTD enhances SKOV3 tumor cell growth, colony formation in soft agar and enhances tumor growth and metastases in SCID mice. In addition, MUC16CTD expression increases cell motility, invasiveness, and metastatic property. Deletion of the cytoplasmic tail from the MUC16CTD completely abolished its ability to enhance tumor cell growth, cell motility and invasiveness. Furthermore, the increased invasive properties of MUC16CTD-expressing cells correlated with decreased expression of E-cadherin and increased expression of N-cadherin and vimentin.
CONCLUSION: These findings provide the first evidence for a critical role of MUC16 in tumor cell growth, tumorigenesis and metastases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421261     DOI: 10.1016/j.ygyno.2011.02.020

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  70 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

2.  MUC16 suppresses human and murine innate immune responses.

Authors:  Mildred Felder; Arvinder Kapur; Alexander L Rakhmilevich; Xiaoyi Qu; Paul M Sondel; Stephen D Gillies; Joseph Connor; Manish S Patankar
Journal:  Gynecol Oncol       Date:  2019-01-06       Impact factor: 5.482

3.  MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53.

Authors:  Imayavaramban Lakshmanan; Shereen Salfity; Parthasarathy Seshacharyulu; Satyanarayana Rachagani; Abigail Thomas; Srustidhar Das; Prabin D Majhi; Rama Krishna Nimmakayala; Raghupathy Vengoji; Subodh M Lele; Moorthy P Ponnusamy; Surinder K Batra; Apar Kishor Ganti
Journal:  Clin Cancer Res       Date:  2017-02-14       Impact factor: 12.531

4.  SNAPR: a bioinformatics pipeline for efficient and accurate RNA-seq alignment and analysis.

Authors:  Andrew T Magis; Cory C Funk; Nathan D Price
Journal:  IEEE Life Sci Lett       Date:  2015-08-28

5.  Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.

Authors:  Isabelle Matte; Clara Major Legault; Perrine Garde-Granger; Claude Laplante; Paul Bessette; Claudine Rancourt; Alain Piché
Journal:  Clin Exp Metastasis       Date:  2016-09-09       Impact factor: 5.150

6.  MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Authors:  Panagiota Giannakouros; Marina Comamala; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

7.  Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.

Authors:  Brandon Nemieboka; Sai Kiran Sharma; Thapi Dharma Rao; Kimberly J Edwards; Su Yan; Pei Wang; Ashwin Ragupathi; Alessandra Piersigilli; David R Spriggs; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2020-05-01       Impact factor: 2.408

Review 8.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

9.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

10.  Immunobiology of human mucin 1 in a preclinical ovarian tumor model.

Authors:  R A Budiu; E Elishaev; J Brozick; M Lee; R P Edwards; P Kalinski; A M Vlad
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.